We serve 1,2-BIS(DICHLOROMETHYLSILYL)ETHANE CAS:3353-69-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:1,2-BIS(DICHLOROMETHYLSILYL)ETHANE
CAS.NO:3353-69-3
Synonyms:1,2-bis(dichloromethylsily)ethane; Ethylenebis(methyldichlorosilane);
1,2-bis(dichloro(methyl)silyl)ethane; 1,2-ethanediylbis[dichloromethyl-Silane;
1,2-ethanediylbis[dichloromethyl-silan;
Molecular Formula:C4H10Cl4Si2
Molecular Weight:256.10500
Physical and Chemical Properties:
Density:1.21;
Boiling point:208-210oC;
Flash point:94oC;
Index of Refraction:1.476;
Specification:
Appearance:Colorless transparent liquid
Purity(GC):≥99.0%
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:As additive used in advanced functional materials.
Contact us for information like 1,2-BIS(DICHLOROMETHYLSILYL)ETHANE chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1,2-ethanediylbis[dichloromethyl-silan physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1,2-ethanediylbis[dichloromethyl-Silane Use and application,1,2-bis(dichloro(methyl)silyl)ethane technical grade,usp/ep/jp grade.
Related News: Beta Bionics, Inc. recently announced it has received Breakthrough Device designation from the US FDA for its investigational iLet Bionic Pancreas System.2-Bromo-4,5-difluorobenzaldehyde manufacturer The safety and effectiveness of TCM is still debated in China, where it has both adherents and skeptics.2-Acetyl-3-fluoropyridine supplier The safety and effectiveness of TCM is still debated in China, where it has both adherents and skeptics.4-chloro-7-methoxyquinoline-6-carboxamide vendor As proof-of-principle for the unique advantages arising from selecting a single engineered iPSC clone for the production of CAR T-cell therapy, the scientists assessed 747 clones after engineering a pool of cells using CRISPR. It was found that only about 2% of clones met the Company’s standards for overall quality including containing both bi-allelic disruption of the TCR, proper insertion of the CAR into the TRAC locus without random transgene integrations, and no evidence of off-target genomic modifications or translocations.As proof-of-principle for the unique advantages arising from selecting a single engineered iPSC clone for the production of CAR T-cell therapy, the scientists assessed 747 clones after engineering a pool of cells using CRISPR. It was found that only about 2% of clones met the Company’s standards for overall quality including containing both bi-allelic disruption of the TCR, proper insertion of the CAR into the TRAC locus without random transgene integrations, and no evidence of off-target genomic modifications or translocations.
